Track market-moving stories before they get noisy

HOUSTON and LONDON, May 22, 2026 (GLOBE NEWSWIRE) -- LyondellBasell (NYSE: LYB) today announced it has declared a dividend of $0.69 per share, to be paid to shareholders on June 8, 2026, with an ex-dividend and record date of June 1, 2026.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are undervalued, leaving room for profits.

Luckily, Zacks has developed its own Style Scores system in an effort to find stocks with specific traits. Value investors will be interested in the system's "Value" category. Stocks with both "A" grades in the Value category and high Zacks Ranks are among the strongest value stocks on the market right now.

One company to watch right now is LyondellBasell Industries (LYB - Free Report) . LYB is currently sporting a Zacks Rank #1 (Strong Buy), as well as an A grade for Value. The stock has a Forward P/E ratio of 12.75. This compares to its industry's average Forward P/E of 13.47. Over the past year, LYB's Forward P/E has been as high as 14.89 and as low as 8.44, with a median of 11.25.

Investors should also recognize that LYB has a P/B ratio of 1.4. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. This company's current P/B looks solid when compared to its industry's average P/B of 2.08. Over the past year, LYB's P/B has been as high as 2.33 and as low as 1.30, with a median of 1.78.

Value investors also use the P/S ratio. The P/S ratio is calculated as price divided by sales. This is a popular metric because sales are harder to manipulate on an income statement, so they are often considered a better performance indicator. LYB has a P/S ratio of 0.73. This compares to its industry's average P/S of 0.76.

These are just a handful of the figures considered in LyondellBasell Industries's great Value grade. Still, they help show that the stock is likely being undervalued at the moment. Add this to the strength of its earnings outlook, and we can clearly see that LYB is an impressive value stock right now.

Note: The following is an excerpt from this week’sEarnings Trends report. You can access the full report that contains detailed historical actual and estimates for the current and following periods, please click here>>>

Here are the key points:

Total Q2 earnings for the S&P 500 index are currently expected to be up +21.8% from the same period last year on +10.9% higher revenues, with 11 of the 16 Zacks sectors expected to enjoy positive earnings growth.Q2 earnings estimates have been steadily going up since the quarter got underway, with the current +21.8% growth rate up from +18% at the start of April. Estimates have increased for 5 of the 16 Zacks sectors, including the Tech, Energy, Basic Materials, Utilities, and Business Services sectors.Q2 earnings are expected to be above the year-earlier level for 11 of the 16 Zacks sectors, with strong growth expected at the Energy (+114.0% earnings growth), Basic Materials (+47.1%), Tech (+43.6%), Utilities (+14.6%), Aerospace (+10.8%), and Industrial Products (+10.2%) sectors. The Tech sector has been a critical growth pillar since 2023 Q3 and is expected to continue playing that role in 2026 Q2, with earnings growth of +43.6%. Excluding the Tech sector’s substantial contribution, Q2 earnings growth for the rest of the S&P 500 index would be +11.4% (vs. +21.8% otherwise).The Revisions Trend Remains PositiveThe overall earnings picture continues to be of all-around strength and a steadily improving outlook. This favorable earnings backdrop is evident in the revisions trend, as seen in how expectations for 2026 Q2 have evolved in recent weeks.

Image Source: Zacks Investment Research

We should note that Q2 estimates have resumed their upward trajectory in recent days, after modestly declining in the days prior to that, even though the overall revisions trend remains positive.

The sectors enjoying positive estimate revisions since the start of April include Energy, Tech, Basic Materials, Utilities, and Business Services. Aggregate Q2 earnings estimates would still be positive since the start of the period, even without favorable revisions for the Energy sector, but aggregate estimates would be down if we exclude the increases in the Energy and Tech sector estimates.

The Tech sector has been enjoying positive estimate revisions for more than a year now, so the sector’s ongoing positive revisions trend is basically more of the same. We have discussed in this space the positive revisions that the Mag 7 group has been experiencing. The Energy sector’s improved earnings outlook is a direct result of the Iran war, as is the upgraded earnings outlook for parts of the Basic Materials sector, particularly the Chemicals industry.

Take, for example, the evolution of Q2 EPS estimates for Dow (DOW - Free Report) , LyondellBasell Industries (LYB - Free Report) , Methanex (MEOH - Free Report) , and others. For Dow and LyondellBasell, the Zacks Consensus EPS estimates for Q2 have more than doubled over the past month, while the same for Methanex has increased by more than 30%.

On the negative side, Q2 estimates have come under renewed pressure since the start of the period for the Transportation, Autos, Medical, and Consumer Discretionary sectors.

The chart below shows S&P 500 expectations for 2026 Q2 in terms of what was achieved in the preceding four periods and what is currently expected for the following three quarters.

Image Source: Zacks Investment Research

The chart below shows the overall earnings picture for the S&P 500 index on an annual basis.

Image Source: Zacks Investment Research

As with estimates for Q2, estimates for full-year 2026 have also been steadily going up, particularly since the start of March. The chart below shows the evolution of aggregate S&P 500 earnings estimates since last July.

Image Source: Zacks Investment Research

Full-year 2026 earnings estimates have increased for 11 of the 16 Zacks sectors since the start of March, with the most pronounced gains at the Energy, Basic Materials, Tech, Industrials, Utilities, and Business Services sectors. On the negative side, estimates have been under pressure for the Transportation, Autos, Medical, and Consumer Discretionary sectors since the start of March.

AbbVie (ABBV) closed at $227.23 in the latest trading session, marking a +1.02% move from the prior day.

Data being presented, including six oral presentations, reinforce AbbVie's leadership and commitment to ongoing research to improve outcomes for people living with blood cancers , /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it will share new data at the European Hematology Association (EHA) 2026 Congress and will showcase clinical advancements from research programs across multiple blood cancers, including multiple myeloma (MM), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), acute myeloid leukemia (AML) and amyloidosis (AL). Featured data from AbbVie's blood cancer portfolio and pipeline include 21 oral and poster presentations, highlighting the investigational compound etentamig (ABBV-383), and approved therapies, EPKINLY® (epcoritamab-bysp) (TEPKINLY® in the EU), VENCLEXTA® (venetoclax) (VENCLYXTO® in the EU) and DECNUPAZ™ (pivekimab sunirine-pvzy). 

"The compelling data we are presenting at EHA reflect AbbVie's robust portfolio and pipeline and our ongoing work to advance the treatment and understanding of hematologic cancers," said Daejin Abidoye, M.D., vice president, therapeutic area head, oncology, solid tumor and hematology, AbbVie. "With this research, we continue our commitment to pioneering innovative solutions that have the potential to elevate standards of care for patients and help address the most pressing challenges in treating blood cancers."

Key oral presentations of epcoritamab data include:

Treatment impact of epcoritamab with lenalidomide and rituximab in relapsed or refractory (R/R) FL A subgroup analysis of the Phase 3 EPCORE FL-1 trial (NCT05409066) of fixed-duration epcoritamab, in combination with rituximab plus lenalidomide (E+R2) for patients with R/R FL (n=243), was performed to determine if the efficacy benefit and tolerability of E+R2 extended across clinically relevant subgroups, including patients with higher- and lower-risk disease features, compared to R2.1 Between Follicular Lymphoma International Prognostic Index (FLIPI) subgroups, overall response rate (ORR) was numerically higher with E+R2 compared to R2 (FLIPI 0–2, 96.5% vs 84.8%; FLIPI 3–5, 93.0% vs 72.6%).1 A similar trend was seen in those with progression of disease less than or equal to two years from the date of initial frontline therapy (POD24).1 Across the age subgroups, ORR and complete response rates (CRR) for E+R2 and R2 for ≥65 were (94.3% vs 80.2% and 80.7% vs 44.3%, respectively) and <65 (95.5% vs 78.4% and 83.9% vs 54.0%, respectively). Progression-free survival (PFS) hazard ratios (HRs) (95% CIs) for E+R2 and R2 for the NHL-5 low co-morbidity index score were (0.27 [0.17–0.42]) and NHL-5 high + intermediate were (0.14 [0.06–0.29]).1 The E+R2 safety profile across all subgroups was consistent with the overall trial population, with no new safety signals.1 Efficacy data of epcoritamab following systemic therapy in R/R large B-cell lymphoma (LBCL) EPCORE DLBCL-1 (EudraCT No. 2020-003016-27) is a randomized Phase 3 trial in R/R LBCL evaluating epcoritamab, a CD3×CD20 bispecific antibody, monotherapy. The study showed a statistically significant improvement in PFS versus investigator's choice of chemoimmunotherapy (CIT) — either rituximab plus gemcitabine plus oxaliplatin or bendamustine plus rituximab (HR 0.74 [95% CI, 0.60–0.92]; P=0.0059; 24-month PFS: 30% vs 13%). The study did not demonstrate a statistically significant improvement in overall survival (OS) (HR: 0.96 [95% CI, 0.77–1.20]). There was no OS detriment per pre-specified criteria.*2 Epcoritamab reported a CRR of 38% and CIT 26%; (nominal P value 0.0032), duration of response (DOR) (median DOR 37 vs 6 months; duration of complete response (DOCR) NR vs 11 months, respectively) and time to next treatment (TTNT) (7 vs 4 months, respectively; nominal P value <0.0001).2 Higher rates of grade 3–4 infections (30% vs 12%) and any-grade COVID-19 (36% vs 11%) were reported in the epcoritamab arm. Grade 5 treatment-emergent adverse events (TEAEs) occurred in 17% vs 6% (exposure-adjusted, 1.5 vs 1.8 per 100 pt-mo) and were largely attributable to grade 5 COVID-19 (9% vs 2%).2 *OUS the protocol and SAP were amended to include dual primary endpoints of OS and PFS

The following studies featuring venetoclax, etentamig and pivekimab sunirine-pvzy data will also be shared as oral and poster presentations:

Predicted efficacy of venetoclax-based therapies in CLL based on genetic biomarkers Results from the Phase 3 GAIA/CLL13 (NCT02950051) trial evaluating fixed-duration venetoclax-based combinations (with rituximab, obinutuzumab and obinutuzumab plus ibrutinib) as a chemotherapy-free alternative to chemoimmunotherapy (fludarabine, cyclophosphamide and rituximab or bendamustine and rituximab) in fit, previously untreated CLL patients lacking del(17p) or TP53 mutations.3 Venetoclax in combination with rituximab and obinutuzumab plus ibrutinib in previously untreated CLL patients lacking del(17p) or TP53 mutations are investigational combinations not approved in the EU. Efficacy and safety data of venetoclax-obinutuzumab combination in previously untreated CLL Results from the open-label Phase 3 CLL14 trial (NCT02242942) comparing the efficacy and safety of venetoclax in combination with obinutuzumab to obinutuzumab plus chlorambucil in previously untreated patients with CLL and coexisting medical conditions.4 Real-world management practices with venetoclax-based therapy for AML Results from the prospective observational study, REVIVE (NCT03987958), examining the effect of antimicrobial prophylaxis, post-remission administration of G-CSF and treatment initiation setting on safety and effectiveness outcomes with venetoclax plus hypomethylating agents (HMA) in newly diagnosed AML patients unfit for intensive chemotherapy.5 Etentamig in patients with relapsed/refractory multiple myeloma (RRMM) with prior exposure to B-cell maturation antigen (BCMA)-targeted therapy Results from Arm B of the MONVISO study (NCT05650632), evaluating a flat dose of etentamig in patients with RRMM with at least two prior lines of therapy, including triple-class and prior BCMA exposure. The Phase 1b study is assessing dose optimization and safety.6 Etentamig is an investigational therapy not approved in the EU. Longer term safety and efficacy data of etentamig monotherapy in R/R light chain amyloidosis Updated results from M24-209 (NCT06158854), evaluating etentamig monotherapy in BCMA-targeted therapy-naïve patients with relapsed/refractory immunoglobulin light chain amyloidosis. The open-label Phase 1/2 study is assessing dose escalation safety and efficacy.7 Etentamig is an investigational therapy not approved in the EU.  Efficacy data of pivekimab sunirine-pvzy in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) with baseline skin involvement in the CADENZA study Post-hoc analysis from CADENZA (NCT03386513), evaluating the first-line use of pivekimab sunirine-pvzy in patients with BPDCN and varying degrees of skin involvement. The open-label Phase 1/2 study is assessing overall response rate, overall survival and percentage of eligible patients approved to proceed with a stem cell transplant.8 Pivekimab sunirine-pvzy is an investigational therapy not approved in the EU. Details on key oral and poster presentations at the EHA 2026 Congress are available below and the full abstracts are available here.

Oral Presentations: 

Title

Date/Time

Session

Abstract/ Presentation Number

Clinically Relevant Subgroup Analysis from the Randomized Phase 3 EPCORE FL-1 Trial: Treatment (Tx) Effect of Epcoritamab with Lenalidomide and Rituximab (R2) in R/R Follicular Lymphoma (FL)

Thursday, June 11,

17:45 - 18:00 CEST

Oral Session,

K1 Hall

EHA-3041

Short: S229

Results from EPCORE DLBCL-1: Randomized Phase 3 Study of Epcoritamab (Epcor) Vs Investigator's Choice Chemoimmunotherapy (CIT) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL)

Friday, June 12,
17:15 - 17:30 CEST

Oral Session,

Nobel Hall

EHA-2409

Short: S235

Venetoclax-obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia: Final Results of the Randomized CLL14 Study

Friday, June 12,

17:30 - 17:45 CEST

Oral Session,

AE1 Hall

EHA-2488

Short: S146

Genetic Biomarkers Predicting Sustained Efficacy of Venetoclax-based Therapies or CIT in Chronic Lymphocytic Leukemia: Final 5-year Analysis of the GAIA/CLL13 Trial

Friday, June 12,
18:15 - 18:30 CEST

Oral Session,

AE1 Hall

EHA-4841

Short: S149

Phase 1 Dose Escalation Safety and Efficacy of Etentamig in Patients with Relapsed or Refractory Light Chain Amyloidosis

Friday, June 12,
18:15 - 18:30 CEST

Oral Session,

Victoria Hall

EHA-1134

Short: S209

Fixed Duration Venetoclax Plus Epcoritamab Shows Favorable Tolerability and High Response Rates with Early Molecular Responses in R/R CLL/SLL: Interim Analysis of the Randomized HOVON 165/AETHER Trial

Sunday, June 14,
11:45 - 12:00 CEST

Oral Session,

A10-11 Hall

EHA-3784

Short: S153

Poster Presentations:

Sustained Remissions Beyond 4 Years with Epcoritamab Monotherapy: Long-term Follow-up Results from the Pivotal EPCORE NHL-1 Trial in Patients with Relapsed or Refractory Large B-cell Lymphoma

Friday, June 12,
18:45 CEST

Poster Session, Hall A

EHA-2191

Short: PF977

Epcoritamab + R-mini-chop Results In 2-year Remissions and High MRD-negativity Rates in Elderly Patients with Newly Diagnosed DLBCL: Results from the EPCORE NHL-2 Trial

Friday, June 12,
18:45 CEST

Poster Session,

Hall A

EHA-2359

Short: PF1007

Reduced CD20 Expression and Intratumoral CD3+ T Cells Following Epcoritamab Treatment Are Associated with Progressive Disease in a Subset of Diffuse Large B-cell Lymphoma and Follicular Lymphoma

Friday, June 12,
18:45 CEST

Poster Session, Hall A

EHA-2343

Short: PF1069

Pharmacodynamic Biomarkers Support the Clinical Benefit of Epcoritamab Plus Rituximab and Lenalidomide (R2) In Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL): Analyses from EPCORE FL-1

Friday, June 12,
18:45 CEST

Poster Session, Hall A

EHA-3123

Short: PF1081

Real-world Management Practices with Venetoclax-based Therapy For AML - Results from the Prospective REVIVE Study

Friday, June 12,
18:45 CEST

Poster Session,

Hall A

EHA-3291

Short: PF536

The Efficacy of Pivekimab Sunirine (PVEK) in Patients (PTS) with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) with Baseline Skin Involvement in the CADENZA Study

Friday, June 12,
18:45 CEST

Poster Session,

Hall A

EHA-1950

Short: PF500

Anchored Matching-adjusted Indirect Comparison of Epcoritamab, Lenalidomide, and Rituximab Vs Tafasitamab, Lenalidomide, and Rituximab in Relapsed/Refractory Follicular Lymphoma: EPCORE FL-1 Vs Inmind

Saturday, June 13,
18:45 CEST

Poster Session, Hall A

EHA-1124

Short: PS2035

Comparative Effectiveness of Epcoritamab, Lenalidomide, and Rituximab in EPCORE FL-1 Vs Real-world Chemoimmunotherapy in Relapsed/Refractory Follicular Lymphoma

Saturday, June 13,
18:45 CEST

Poster Session, Hall A

EHA-3065

Short: PS2042

Comparative Analyses of Epcoritamab in Combination with Lenalidomide and Rituximab Vs Obinutuzumab and Bendamustine in Relapsed/Refractory Follicular Lymphoma

Saturday, June 13,
18:45 CEST

Poster Session, Hall A

EHA-3140

Short: PS2052

Epcoritamab + Chemoimmunotherapy in Patients with Relapsed/Refractory Large B-cell Lymphoma Eligible for Autologous Stem Cell Transplant: Pooled Results from Arms 4 and 10 of EPCORE NHL-2

Saturday, June 13,
18:45 CEST

Poster Session,

Hall A

EHA-2303

Short: PS2070

Fixed-duration Epcoritamab Monotherapy Induces High Response and MRD-negativity Rates in Elderly Patients with Newly Diagnosed Large B-cell Lymphoma and Comorbidities: Results from EPCORE DLBCL-3

Saturday, June 13,
18:45 CEST

Poster Session, Hall A

EHA-2346

Short: PS2082

Epcoritamab In Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL): Insights from the Real-world Epcoritamab Patient Characteristics and Outcomes Research (Real-epcor) Study

Saturday, June 13,
18:45 CEST

Poster Session, Hall A

EHA-2202

Short: PS2086

Epcoritamab Plus Lenalidomide and Rituximab Improves or Preserves Health-related Quality of Life in Patients with Relapsed/Refractory Follicular Lymphoma Who Had High Symptom Burden or Adverse Events

Saturday, June 13,
18:45 CEST

Poster Session, Hall A

EHA-2776

Short: PS2497

Quality of Life and Symptoms with Fixed-duration Acalabrutinib + Venetoclax ± Obinutuzumab Vs Chemoimmunotherapy in Treatment-naive Chronic Lymphocytic Leukemia: Patient-Reported Outcomes from AMPLIFY

Saturday, June 13,
18:45 CEST

Poster Session,

Hall A

EHA-4662

Short: PS1706

Etentamig In Patients (PTS) with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to B-cell Maturation Antigen (BCMA)-targeted Therapy

Saturday, June 13,
18:45 CEST

Poster Session,

Hall A

EHA-2799

Short: PS1913

Etentamig (ABBV-383) is an investigational medicine and is not approved by any health authorities worldwide. The safety and efficacy of this medicine is under evaluation as part of ongoing clinical studies. Pivekimab sunirine is not approved in the EU.

EPKINLY®/TEPKINLY® (epcoritamab) and VENCLEXTA®/VENCLYXTO® (venetoclax) are approved medicines being investigated for additional uses. Safety and efficacy have not been established for these unapproved additional uses.

EPKINLY®/TEPKINLY® (epcoritamab) is being co-developed by Genmab and AbbVie as part of the companies' oncology collaboration. The companies share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization. 

VENCLEXTA®/VENCLYXTO® (venetoclax) is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S.

Additional information on AbbVie clinical trials is available at https://www.clinicaltrials.gov/. 

USE & IMPORTANT SAFETY INFORMATION for EPKINLY® (epcoritamab-bysp) in U.S.

What is EPKINLY?
EPKINLY is a prescription medicine used to treat adults with:

certain types of diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma that has come back (relapsed) or that did not respond (refractory) after 2 or more treatments. follicular lymphoma (FL) that has come back or that did not respond to previous treatment, together with lenalidomide and rituximab follicular lymphoma (FL) that has come back or that did not respond after 2 or more treatments. EPKINLY for the treatment of DLBCL is approved based on patient response data. Studies are ongoing to confirm the clinical benefit of EPKINLY.

It is not known if EPKINLY is safe and effective in children.

IMPORTANT SAFETY INFORMATION
Important Warnings—EPKINLY can cause serious side effects, including:

Cytokine release syndrome (CRS), which is common during treatment with EPKINLY and can be serious or lead to death. To help reduce your risk of CRS, you will receive EPKINLY on a step-up dosing schedule (when you receive 2 or 3 smaller step-up doses of EPKINLY before your first full dose during your first cycle of treatment), and you may also receive other medicines before and for 3 days after receiving EPKINLY. If your dose of EPKINLY is delayed for any reason, you may need to repeat the step-up dosing schedule. Neurologic problems that can be serious, and can be life-threatening, and lead to death. Neurologic problems may happen days or weeks after you receive EPKINLY. People with DLBCL or high-grade B-cell lymphoma may be hospitalized after receiving their first full dose of EPKINLY on Day 15 of Cycle 1 due to the risk of CRS and neurologic problems.

People with FL may be hospitalized after receiving their first full dose of EPKINLY on Day 22 of Cycle 1 due to the risk of CRS and neurologic problems.

Tell your healthcare provider or get medical help right away if you develop a fever of 100.4°F (38°C) or higher; dizziness or lightheadedness; trouble breathing; chills; fast heartbeat; feeling anxious; headache; confusion; shaking (tremors); problems with balance and movement, such as trouble walking; trouble speaking or writing; confusion and disorientation; drowsiness, tiredness or lack of energy; muscle weakness; seizures; or memory loss. These may be symptoms of CRS or neurologic problems. If you have any symptoms that impair consciousness, do not drive or use heavy machinery or do other dangerous activities until your symptoms go away.

EPKINLY can cause other serious side effects, including:

Infections that may lead to death. Your healthcare provider will check you for signs and symptoms of infection before and during treatment and treat you as needed if you develop an infection. You should receive medicines from your healthcare provider before you start treatment to help prevent infection. Tell your healthcare provider right away if you develop any symptoms of infection during treatment, including fever of 100.4°F (38°C) or higher, cough, chest pain, tiredness, shortness of breath, painful rash, sore throat, pain during urination, feeling weak or generally unwell, or confusion. Low blood cell counts, which can be serious or severe. Your healthcare provider will check your blood cell counts during treatment. EPKINLY may cause low blood cell counts, including low white blood cells (neutropenia and lymphopenia), which can increase your risk for infection; low red blood cells (anemia), which can cause tiredness and shortness of breath; and low platelets (thrombocytopenia), which can cause bruising or bleeding problems. Your healthcare provider will monitor you for symptoms of CRS, neurologic problems, infections, and low blood cell counts during treatment with EPKINLY. Your healthcare provider may temporarily stop or completely stop treatment with EPKINLY if you develop certain side effects.

Before you receive EPKINLY, tell your healthcare provider about all your medical conditions, including if you have an infection, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. If you receive EPKINLY while pregnant, it may harm your unborn baby. If you are a female who can become pregnant, your healthcare provider should do a pregnancy test before you start treatment with EPKINLY and you should use effective birth control (contraception) during treatment and for 4 months after your last dose of EPKINLY. Tell your healthcare provider if you become pregnant or think that you may be pregnant during treatment with EPKINLY. Do not breastfeed during treatment with EPKINLY and for 4 months after your last dose of EPKINLY.

The most common side effects of EPKINLY when used alone in DLBCL or high-grade B-cell lymphoma or FL include CRS, injection site reactions, tiredness, muscle and bone pain, fever, diarrhea, COVID-19, rash, and stomach-area (abdominal) pain. The most common severe abnormal laboratory test results with EPKINLY when used alone include decreased white blood cells, decreased red blood cells, and decreased platelets.

The most common side effects of EPKINLY when used together with lenalidomide and rituximab in FL include rash, upper respiratory tract infections, tiredness, injection site reactions, constipation, diarrhea, CRS, pneumonia, COVID-19, and fever. The most common severe abnormal laboratory test results with EPKINLY when used together with lenalidomide and rituximab include decreased white blood cells and decreased platelets.

These are not all of the possible side effects of EPKINLY. Call your doctor for medical advice about side effects.

You are encouraged to report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch or to Genmab US, Inc. at 1-855-4GENMAB (1-855-443-6622).

Please see Full Prescribing Information and Medication Guide, including Important Warnings.

Globally, prescribing information varies. Refer to the individual country product label for complete information.

USE & IMPORTANT SAFETY INFORMATION for VENCLEXTA® (venetoclax tablets) in U.S.

Uses

VENCLEXTA is a prescription medicine used:

to treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). in combination with azacitidine, or decitabine, or low-dose cytarabine to treat adults with newly diagnosed acute myeloid leukemia (AML) who:
‒ are 75 years of age or older, or
‒ have other medical conditions that prevent the use of standard chemotherapy. It is not known if VENCLEXTA is safe and effective in children.

Important Safety Information

What is the most important information I should know about VENCLEXTA?

VENCLEXTA can cause serious side effects, including: 
Tumor lysis syndrome (TLS). TLS is caused by the fast breakdown of cancer cells. TLS can cause kidney failure, the need for dialysis treatment, and may lead to death. Your healthcare provider will do tests to check your risk of getting TLS before you start taking VENCLEXTA. You will receive other medicines before starting and during treatment with VENCLEXTA to help reduce your risk of TLS. You may also need to receive intravenous (IV) fluids into your vein. Your healthcare provider will do blood tests to check for TLS when you first start and during treatment with VENCLEXTA. It is important to keep your appointments for blood tests. Tell your healthcare provider right away if you get any symptoms of TLS during treatment with VENCLEXTA, including fever, chills, nausea, vomiting, confusion, shortness of breath, seizures, irregular heartbeat, dark or cloudy urine, unusual tiredness, or muscle or joint pain.

Drink plenty of water during treatment with VENCLEXTA to help reduce your risk of getting TLS. Drink 6 to 8 glasses (about 56 ounces total) of water each day, starting 2 days before your first dose, on the day of your first dose of VENCLEXTA, and each time your dose is increased.

Your healthcare provider may delay, decrease your dose, or stop treatment with VENCLEXTA if you get symptoms of TLS. When restarting VENCLEXTA after stopping for 1 week or longer, your healthcare provider may check again for your risk of TLS and change your dose.

Who should not take VENCLEXTA?

Patients taking certain medicines during the beginning of VENCLEXTA (when the dose is being slowly increased) are at increased risk of TLS.

Tell your healthcare provider about all the medicines you take, including prescription and over-the- counter medicines, vitamins, and herbal supplements. VENCLEXTA and other medicines may affect each other causing serious side effects. Do not start new medicines during treatment with VENCLEXTA without first talking with your healthcare provider. Before taking VENCLEXTA, tell your healthcare provider about all of your medical conditions, including if you:

have kidney or liver problems. have problems with your body salts or electrolytes, such as potassium, phosphorus, or calcium. have a history of high uric acid levels in your blood or gout. are scheduled to receive a vaccine. You should not receive a "live vaccine" before, during, or after treatment with VENCLEXTA, until your healthcare provider tells you it is okay. If you are not sure about the type of immunization or vaccine, ask your healthcare provider. These vaccines may not be safe or may not work as well during treatment with VENCLEXTA. are pregnant or plan to become pregnant. VENCLEXTA may harm your unborn baby.
 Females who are able to become pregnant:
 ‒ Your healthcare provider should do a pregnancy test before you start treatment with VENCLEXTA.
 ‒ Use effective birth control during treatment and for 30 days after the last dose of VENCLEXTA.
 ‒ If you become pregnant or think you are pregnant, tell your healthcare provider right away. are breastfeeding or plan to breastfeed. It is not known if VENCLEXTA passes into your breast milk. Do not breastfeed during treatment with VENCLEXTA and for 1 week after the last dose. What should I avoid while taking VENCLEXTA? 
You should not drink grapefruit juice or eat grapefruit, Seville oranges (often used in marmalades), or starfruit during treatment with VENCLEXTA. These products may increase the amount of VENCLEXTA in your blood.

What are the possible side effects of VENCLEXTA?

VENCLEXTA can cause serious side effects, including:

Low white blood cell counts (neutropenia). Your healthcare provider will do blood tests to check your blood count during treatment with VENCLEXTA and may pause dosing of VENCLEXTA or give you medicines to help treat your neutropenia if it is severe. Infections. Death and serious infections such as pneumonia and blood infection (sepsis) have happened during treatment with VENCLEXTA. Your healthcare provider will closely monitor and treat you right away if you get a fever or any signs of infection during treatment with VENCLEXTA. Tell your healthcare provider right away if you get a fever or any signs of an infection during treatment with VENCLEXTA.

The most common side effects of VENCLEXTA when used in combination with acalabrutinib in people with CLL or SLL include low white blood cell count, headache, diarrhea, muscle and bone pain, and COVID-19.

The most common side effects of VENCLEXTA when used in combination with obinutuzumab or rituximab or alone in people with CLL or SLL include low white blood cell count; low platelet count; low red blood cell count; diarrhea; nausea; upper respiratory tract infection; cough; muscle and joint pain; tiredness; and swelling of your arms, legs, hands, and feet.

The most common side effects of VENCLEXTA in combination with azacitidine or decitabine or low-dose cytarabine in people with AML include nausea; diarrhea; low platelet count; constipation; low white blood cell count; fever with low white blood cell count; tiredness; vomiting; swelling of arms, legs, hands, or feet; fever; infection in lungs; shortness of breath; bleeding; low red blood cell count; rash; stomach (abdominal) pain; infection in your blood; muscle and joint pain; dizziness; cough; sore throat; and low blood pressure.

Your healthcare provider may temporarily stop VENCLEXTA treatment, decrease your dose, or completely stop treatment if you get severe side effects.

VENCLEXTA may cause fertility problems in males. This may affect your ability to father a child. Talk to your healthcare provider if you have concerns about fertility.

These are not all the possible side effects of VENCLEXTA. Call your doctor for medical advice about side effects.

You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

If you cannot afford your medication, contact genentech-access.com/patient/brands/venclexta for assistance.

Please see full Prescribing Information. Globally, prescribing information varies. Refer to the individual country product label for complete information. 

U.S. Prescribing Information for AbbVie Medicines

Please see full Prescribing Information including BOXED WARNING for DECNUPAZ (pivekimab sunirine-pvzy)

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.

About AbbVie in Oncology

AbbVie is committed to elevating standards of care and bringing transformative therapies to patients worldwide living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibody and novel CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.

Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood cancers and solid tumors. We are evaluating more than 35 investigational medicines in multiple clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology.

Forward-Looking Statements

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

Contacts:

_________________________________

1

Tessoulin B, Nijland M, et al. Clinically Relevant Subgroup Analysis From The Randomized Phase 3 EPCORE FL-1 Trial: Treatment (Tx) Effect Of Epcoritamab With Lenalidomide And Rituximab (R²) In R/R Follicular Lymphoma (Fl). Abstract EHA-3041 presented at the European Hematology Association Congress 2026. Stockholm, Sweden.  

2

Fox C, Inchiappa L, et al. Results From EPCORE DLBCL-1: Randomized Phase 3 Study Of Epcoritamab (Epcor) Vs Investigator's Choice Chemoimmunotherapy (Cit) In Patients With Relapsed/Refractory Large B-Cell Lymphoma (R/R Lbcl). Abstract EHA-2409 presented at the European Hematology Association Congress 2026. Stockholm, Sweden.  

3

Tausch E, Schneider C, et al. Genetic Biomarkers Predicting Sustained Efficacy of Venetoclax-based Therapies or CIT in Chronic Lymphocytic Leukemia: Final 5-yr Analysis of the GAIA/CLL13 Trial. Abstract EHA-4841 presented at the European Hematology Association Congress 2026. Stockholm, Sweden.   

4

Fischer K, Al-Sawaf O ,et al. Venetoclax-obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia: Final Results of the Randomized CLL14 Study. Abstract EHA-2488 presented at the European Hematology Association Congress 2026. Stockholm, Sweden.  

5

Moshe Y, Wolach O, et al. Real-world Management Practices with Venetoclax-based Therapy For AML- Results from the Prospective REVIVE Study. Abstract EHA- 3291 presented at the European Hematology Association Congress 2026. Stockholm, Sweden.  

6

Chhabra S, Searle E, et al. Etentamig In Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to B-cell Maturation Antigen (BCMA)-targeted Therapy. Abstract EHA-2799 presented at the European Hematology Association Congress 2026. Stockholm, Sweden.  

7

Kastritis E, Huart A, et al. Phase 1 Dose Escalation Safety and Efficacy of Etentamig in Patients with Relapsed or Refractory Light Chain Amyloidosis. Abstract EHA-1134 presented at the European Hematology Association Congress 2026. Stockholm, Sweden.  

8

Pemmaraju N, Marconi G, et al. Efficacy of pivekimab sunirine-pvzy in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) with baseline skin involvement in the CADENZA study Abstract EHA-1950 presented at the European Hematology Association Congress 2026. Stockholm, Sweden.  

SOURCE AbbVie

A retiree's $40,000 dividend income stream sounds modest next to a neighbor's $90,000. But the growth rate often matters more than the starting number. A portfolio generating $40,000 today that grows its income by 8% annually produces roughly $86,000 in ten years and more than $186,000 in twenty. That is the power of compounding. The... The Dividend Growth Portfolio That Starts at $40,000 a Year and Ends at $150,000

AbbVie Inc. (ABBV) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Mid-year is when income-focused investors tend to take a hard look at their portfolios. With the second half of 2026 ahead, retirees and near-retirees are leaning into reliable dividend payers that can keep checks coming through any summer volatility. The three names below combine long dividend histories, defensive cash flows, and recent raises, exactly the profile that holds up when growth stocks wobble.

Verizon (NYSE: VZ) Verizon (NYSE:VZ | VZ Price Prediction) is the high-yield anchor of this list. The stock trades at $46.95 with a trailing P/E of just 11 and a dividend yield around 6%, well above the broader market. The Q2 2026 payout was raised to $0.7075 per share, up from $0.69 the prior quarter, extending one of the longest uninterrupted dividend streaks in U.S. telecom.

The bull case is straightforward for retirees. Q1 2026 adjusted EPS came in at $1.28, up 8% YoY, and management raised full-year guidance to $4.95 to $4.99 in adjusted EPS with free cash flow of at least $21.5 billion, which more than covers the dividend. The closed Frontier Communications acquisition pushed fiber broadband connections up 42% YoY to roughly 10.8 million, and Verizon posted its first positive Q1 postpaid phone net adds since 2013. CEO Dan Schulman summed it up: “Our turnaround is not only progressing, it is gaining momentum.” Shares are up 16% year to date, yet still trade below the analyst target of $51.85.

Risk to watch: Total debt climbed to $172.5 billion after the Frontier deal, interest expense rose 19% YoY, and postpaid phone churn ticked up to 1%. Leverage will dictate how quickly future raises arrive.

Chevron (NYSE: CVX) Chevron (NYSE:CVX) is the dividend aristocrat of the group. The Q1 2026 dividend was raised to $1.78 per share quarterly, marking the 39th consecutive annual increase. That payment landed in shareholder accounts on June 10, 2026, the same day this article runs. Shares closed at $186.76 on June 9 and have risen 25% year to date, yet the forward P/E sits at a reasonable 14.

The retirement thesis here is fortress cash returns. Chevron posted Q1 2026 adjusted EPS of $1.41 versus $0.97 estimates, its sixth consecutive quarterly EPS beat. Worldwide production rose 15% YoY to 3,858 MBOED, with the Permian Basin now at 1 million BOE/day following Hess integration. Chevron has returned cash on autopilot, posting 16 consecutive quarters returning more than $5 billion to shareholders, including $2.5 billion in Q1 buybacks. CEO Mike Wirth pointed to “the resilience of our portfolio and the value of disciplined execution.”

Risk to watch: Q1 net income fell 37% YoY, free cash flow turned negative at -$1.55 billion on working capital swings, and the net debt ratio crept to 18%. Oil-price sensitivity and Middle East exposure remain the obvious wildcards.

AbbVie (NYSE: ABBV) AbbVie (NYSE:ABBV) rounds out the trio as the healthcare leg. The stock closed at $225.42 on June 9 with a dividend yield near 3% and a forward P/E of 16. The dividend was raised to $1.73 per quarter in 2026, up from $1.64, continuing a march from just $0.40 per quarter in 2013.

The plain-language bull case: the post-Humira transition is going faster than skeptics expected. Q1 2026 revenue hit $15.00 billion, up 12% YoY, beating the $14.72 billion estimate. Skyrizi grew 31% YoY to $4.48 billion, Rinvoq added 23%, and neuroscience expanded 26%. Management raised 2026 adjusted EPS guidance to $14.08 to $14.28. CEO Robert A. Michael said the company is “off to an excellent start in 2026, with first-quarter results exceeding our expectations.” Analysts carry an average target of $253.55.

Risk to watch: Humira sales fell 39% to $688 million as biosimilars bite, Imbruvica dropped 25%, and GAAP earnings remain weighed down by acquired IPR&D charges. Investors will want to see Skyrizi and Rinvoq continue carrying the load past 2028.

What to Watch Next All three names share the traits retirement portfolios tend to prize: long dividend histories, recent raises, defensive end markets, and forward P/E ratios in the low-to-mid teens. Verizon offers the deepest yield, Chevron the longest aristocrat streak, and AbbVie the best growth profile of the group. Keep an eye on Q2 earnings reports later this summer, when each management team will update guidance heading into the second half.

AbbVie (NYSE:ABBV | ABBV Price Prediction) at $224.95 sits at the center of a sharp bull-bear debate. The pharma giant has climbed 53.59% since the start of 2024 off its 2024 lows, but a balance sheet carrying negative shareholders’ equity of -$6.6 billion complicates conviction at this price.

AbbVie is the immunology heavyweight behind Skyrizi, Rinvoq, and legacy Humira, with neuroscience, oncology, and aesthetics portfolios from the 2020 Allergan deal. The stock has run on smoother-than-feared Humira biosimilar transition and aggressive growth from next-generation immunology drugs.

That run has stretched valuation to a trailing P/E near 110 while shareholder equity has flipped negative, leaving the market to decide whether the cash machine deserves a premium or leverage deserves a discount.

Why Skyrizi And Rinvoq Justify The Premium Skyrizi delivered $4.48 billion in Q1 2026 revenue, up 30.9%, and Rinvoq added $2.12 billion, up 23.3%. Both drugs are absorbing Humira’s erosion faster than analysts modeled a year ago.

Management raised FY2026 adjusted EPS guidance to $14.08 to $14.28, the second hike of the cycle. Neuroscience grew 26.0% to $2.88 billion, with Ubrelvy and Qulipta both posting growth above 40%. The Street sees upside, with 24 Buy ratings and an average price target of $253.55.

Free cash flow yield of 4.48% and a 2.93% dividend yield, backed by the $1.73 quarterly payout raised in late 2025, give income investors a paid-to-wait setup with Dividend Aristocrat pedigree.

The Leverage And Patent Cliff Bears Are Watching Total debt sits at $72.86 billion as of Q1 2026, against shareholder equity of -$6.6 billion and retained earnings of -$17.87 billion. Equity has eroded by roughly $13.6 billion in two years.

Interest expense ran $2.89 billion in FY2025 and is structural drag if rates stay elevated. 65.9% of assets are goodwill and intangibles, much tied to Allergan, leaving thin tangible backing for $143 billion in liabilities.

Q1 2026 net income fell 45.7% year over year to $699 million, hit by IPR&D charges and a $2.39 billion contingent consideration adjustment. One in-house AI model pegs fair value at $154.41, implying 31.36% downside.

Why The Middle Ground Wins For Now The Hold case rests on offsetting forces. Skyrizi and Rinvoq are real, the dividend is funded, and the $100 billion U.S. R&D commitment buys three years of tariff and pricing relief. Yet negative book value, a -10.84% ROIC, and patent cliff worry beyond 2028 keep the long-term math fragile.

Adding capital here means paying a high P/E for earnings still eaten by interest, amortization, and acquisition charges. Trimming means giving up a growing dividend and the strongest immunology franchise in pharma. Watching quarterly Skyrizi and Rinvoq sales, debt paydown progress, and pipeline reads from Epkinly, Elahere, or ABBV-295 obesity program is the honest move.

What The Numbers Say ABBV trades at $224.95, with analyst consensus target of $253.55 across 32 covering analysts (24 Buy, 8 Hold, 0 Sell), implying roughly 13% upside if hit. The AI-driven counter-read at $154.41 shows dispersion of views.

The stock is up 22.6% over the past year and roughly flat year to date at +0.07%. The S&P 500 is up 20.29% over the past year and 6.38% year to date, meaning AbbVie matched the index over twelve months but lagged in 2026.

Valuation reads expensive on earnings (P/E near 110) yet reasonable on cash (P/FCF of 22), which is the heart of the debate.

The Verdict On ABBV At $225 At $224.95, AbbVie sits in the middle of the bull-bear debate.

The bull thesis requires continued double-digit growth from Skyrizi and Rinvoq plus successful integration of recent IPR&D bets to refill the pipeline beyond 2028. The bear thesis requires interest expense and amortization to keep suppressing reported earnings while patent cliff fears regain attention. Both paths are live, and current price compensates for neither cleanly.

Existing holders are paid $1.73 a quarter to wait for the next two earnings reports, where Skyrizi and Rinvoq run-rates, GAAP cleanup, and any 2028+ pipeline reads will either confirm the premium or expose it. Investors evaluating fresh capital may find a wider margin of safety closer to $190, where the income stream better offsets negative-equity reality.

The verdict shifts on either sharp deceleration in immunology growth (push toward Sell) or visible deleveraging plus pipeline win that resets 2029 earnings (push toward Buy). Until then, the dividend, leverage trajectory, and valuation relative to recent gains are the metrics that matter most.

At $225, AbbVie looks too leveraged to add aggressively yet too productive to dismiss, which is why the debate stays balanced.

, /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new Phase 3 data on a fixed-duration venetoclax-based combination at the European Hematology Association (EHA) 2026 Congress taking place June 11-14 in Stockholm, Sweden. Final results from the Phase 3 CLL14 trial in previously untreated chronic lymphocytic leukemia (CLL), which was conducted in collaboration with the German CLL Study Group, will be featured in an oral presentation.

"The nine-year results from the landmark Phase 3 CLL14 trial affirm venetoclax's enduring safety and efficacy," said Daejin Abidoye, vice president, therapeutic area head, oncology, solid tumor and hematology, AbbVie. "These data continue to add to the impressive body of evidence supporting the first-line use of venetoclax-based combination regimens in broader CLL patient populations, offering patients unprecedented time to next treatment — and therefore time off treatment — after one year of fixed-duration therapy. This research advances our mission to transform care and deliver better outcomes for patients living with difficult-to-cure blood cancers."

"Venetoclax in combination with obinutuzumab has shown positive responses across several key measures compared to obinutuzumab plus chlorambucil, including an extended increase in progression-free survival in previously untreated patients with chronic lymphocytic leukemia," said Kirsten Fischer, M.D., investigator in the CLL14 study, University Hospital Cologne. "Importantly, with a demonstrated median time to next treatment of approximately eight years, the findings reflect the sustained durability of this combination treatment option with a meaningful time without CLL specific treatment for patients."

A final analysis of the Phase 3 CLL14 trial, conducted in close collaboration with the German CLL Study Group, comparing venetoclax plus obinutuzumab to chlorambucil plus obinutuzumab in previously untreated patients with CLL and coexisting medical conditions, found that venetoclax plus obinutuzumab significantly improved progression-free survival (PFS) compared to chlorambucil plus obinutuzumab, providing a limited-duration treatment option for unfit patients with previously untreated CLL. The nine-year analysis demonstrated the long-term off-treatment efficacy and safety of the venetoclax plus obinutuzumab fixed-duration combination, with the median time to next treatment (TTNT) of 7.6 years.1

After a median follow-up of 9.2 years, treatment with venetoclax plus obinutuzumab resulted in superior PFS compared to the obinutuzumab plus chlorambucil group, with median PFS of 6.4 years versus 3.2 years, respectively (HR 0.50 [95% CI 0.39-0.63], p<0.001). The most frequently occurring Grade 3 (≥2%) adverse events (AEs) in patients receiving the venetoclax-based combination were neutropenia, thrombocytopenia, infusion-related reaction, anemia, febrile neutropenia, pneumonia and leukopenia.1,2

CLL is one of the most common forms of leukemia in adults and is a type of cancer that can develop from cells in the bone marrow that later mature into certain white blood cells (called lymphocytes).3 Patients with CLL often experience relapsed disease, meaning the cancer has returned after previously responding to treatment, while others experience refractory disease when the cancer stops responding to therapy.4 While outcomes have improved in recent years, patients can often face long treatment durations and ongoing disease management challenges.

About the CLL14 Phase 3 Trial2,5,6,7

The prospective, multicenter, open-label, randomized Phase 3 CLL14 trial (NCT02242942), which was conducted in close collaboration with the German CLL Study Group (GCLLSG), evaluated the efficacy and safety of a combined regimen of venetoclax and obinutuzumab (n=216) versus obinutuzumab and chlorambucil (n=216) in previously untreated patients with CLL and co-existing medical conditions (total Cumulative Illness Rating Scale [CIRS] score >6 or creatinine clearance <70 mL/min). The therapies were administered for a fixed duration of 12 months for venetoclax in combination with six cycles of obinutuzumab. The trial enrolled 432 patients, all of whom were previously untreated, according to the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria. Efficacy was based on PFS, as assessed by an independent review committee.

Key secondary endpoints were rates of MRD in peripheral blood and bone marrow and overall and complete response rates.

In patients with CLL receiving venetoclax combination therapy with obinutuzumab, the most frequently occurring Grade 3 (≥2%) adverse events (AEs) were neutropenia, thrombocytopenia, infusion-related reaction, anemia, febrile neutropenia, pneumonia and leukopenia.1,2

About VENCLYXTO

VENCLYXTO® (venetoclax) is a first-in-class medicine that selectively binds and inhibits the B-cell lymphoma-2 (BCL-2) protein. In some blood cancers, BCL-2 prevents cancer cells from undergoing their natural death or self-destruction process, called apoptosis. VENCLYXTO targets the BCL-2 protein and works to help restore the process of apoptosis.

VENCLYXTO is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S. Together, the companies are committed to BCL-2 research and to studying venetoclax in clinical trials across several blood and other cancers. Venetoclax is approved in more than 80 countries, including the U.S.

VENCLYXTO (venetoclax) EU Indication and Summary of Important Safety Information

Venclyxto is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL):

in combination with acalabrutinib with or without obinutuzumab in combination with obinutuzumab in combination with ibrutinib VENCLYXTO in combination with rituximab is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.

VENCLYXTO monotherapy is indicated for the treatment of CLL:

In the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor, or In the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor Contraindications
Hypersensitivity to the active substance or to any of the excipients. Concomitant use of strong CYP3A inhibitors at initiation and during the dose-titration phase. Concomitant use of preparations containing St. John's wort.

Special Warnings & Precautions for Use
Tumour lysis syndrome (TLS), including fatal events and renal failure requiring dialysis, has occurred in patients with CLL when treated with venetoclax. Venetoclax poses a risk for TLS at initiation and during the dose-titration phase. Changes in electrolytes consistent with TLS that require prompt management can occur as early as 6 to 8 hours following the first dose of VENCLYXTO and at each dose increase. During post marketing surveillance, TLS, including fatal events, has been reported after a single 20 mg dose of venetoclax. The risk of TLS is a continuum based on multiple factors, including comorbidities (particularly reduced renal function), tumour burden, and splenomegaly in CLL. Patients should be assessed for risk and should receive appropriate prophylaxis, monitoring, and management for TLS.

Neutropenia (grade 3 or 4) has been reported and complete blood counts should be monitored throughout the treatment period. Serious infections, including sepsis with fatal outcome, have been reported. Monitoring of any signs and symptoms of infection is required. Suspected infections should receive prompt treatment and dose interruption or reduction, as appropriate. Live vaccines should not be administered during treatment or thereafter until B-cell recovery.

Drug Interactions
CYP3A inhibitors: For patients requiring concomitant use with venetoclax, refer to the SmPC for recommendations for managing drug-drug interactions. Patients should be monitored more closely for signs of toxicities and the dose may need to be further adjusted. Grapefruit products, Seville oranges, and starfruit (carambola) should be avoided during treatment with venetoclax.

Additional agents that may alter venetoclax plasma concentrations include P-gp or BCRP inhibitors, CYP3A inducers (including St. John's wort), azithromycin and bile acid sequestrants. Concomitant use of these agents with venetoclax may require further dose adjustments and patients should be monitored closely for signs of toxicities.

Adverse Reactions
The most commonly occurring adverse reactions (≥20%) of any grade in patients receiving venetoclax in the combination studies with obinutuzumab, ibrutinib, or rituximab were diarrhoea, neutropenia, nausea, upper respiratory tract infection, fatigue and vomiting. In the monotherapy studies, the most common adverse reactions were neutropenia/neutrophil count decreased, diarrhoea, nausea, anaemia, fatigue, and upper respiratory tract infection.

The most frequently reported serious adverse reactions (≥2%) in patients receiving venetoclax in combination with obinutuzumab, ibrutinib, or rituximab were pneumonia, febrile neutropenia, sepsis, neutropenia, anaemia, diarrhoea and TLS. In the monotherapy studies, the most frequently reported serious adverse reactions (≥2%) were pneumonia and febrile neutropenia.

The most commonly occurring adverse reactions (≥20%) of any grade in patients treated with venetoclax in combination with acalabrutinib were infections, neutropenia, headache, bruising, diarrhoea and musculoskeletal pain. The most commonly reported Grade ≥3 adverse reaction (≥5%) was neutropenia.

The most commonly occurring adverse reactions of any grade (≥20%) in patients treated with venetoclax in combination with acalabrutinib and obinutuzumab were infections, neutropenia, headache, bruising, diarrhoea, nausea and musculoskeletal pain. The most commonly reported Grade ≥3 adverse reactions (≥5%) were neutropenia and thrombocytopenia.

Discontinuations, dosage reductions and dose interruptions due to adverse reactions have occurred in both venetoclax monotherapy and in combination therapy.

Special Populations
Patients with reduced renal function (CrCl <80 mL/min) may require more intensive prophylaxis and monitoring to reduce the risk of TLS at initiation and during the dose-titration phase. Venetoclax should be administered to patients with severe renal impairment (CrCl ≥15 ml/min and <30 ml/min) or end-stage renal disease (ESRD) requiring dialysis (CrCL <15ml/min) only if the benefit outweighs the risk and patients should be monitored closely for signs of toxicity due to increased risk of TLS.

For patients with severe hepatic impairment, a dose reduction of at least 50% throughout treatment is recommended. These patients should be monitored more closely for signs of toxicity.

Women should avoid becoming pregnant while taking venetoclax and for at least 30 days after ending treatment. Therefore, women of childbearing potential must use highly effective contraceptive measures while taking venetoclax and for 30 days after stopping treatment. Venetoclax may harm the foetus when administered to a pregnant woman. Breast-feeding should be discontinued during treatment with venetoclax.

This is not a complete summary of all safety information. Refer to the prescribing information of each of the medicinal products used in combination with venetoclax for additional information for management of toxicities. See VENCLYXTO (venetoclax) SmPC at www.ema.europa.eu. Globally, prescribing information varies. Refer to the individual country product label for complete information.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.

About AbbVie in Oncology

AbbVie is committed to elevating standards of care and bringing transformative therapies to patients worldwide living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibody and novel CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.

Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood cancers and solid tumors. We are evaluating more than 35 investigational medicines in multiple clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology.

Forward-Looking Statements

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. 

Contacts:

_________________________________

1

Fischer K, Al-Sawaf O ,et al. Venetoclax-obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia: Final Results of the Randomized CLL14 Study. Abstract EHA-2488 presented at the European Hematology Association Congress 2026. Stockholm, Sweden.

2

Fischer K, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380:2225-2236.

3

American Cancer Society. Leukemia – Chronic Lymphocytic Leukemia. Available at: https://www.cancer.org/cancer/types/chronic-lymphocytic-leukemia/about/what-is-cll.html. Accessed June 2026.

4

Nastoupil L, Flowers C. Management of relapsed chronic lymphocytic leukemia: applying guidelines to practice. Community Oncol. 2012; 9(12): S85–S92. doi:10.1016/j.cmonc.2012.09.019. 

5

Clinicaltrials.gov. NCT02242942: A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare The Efficacy and Safety of A Combined Regimen of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) Versus Obinutuzumab and Chlorambucil in Previously Untreated Patients With CLL and Coexisting Medical Conditions. Accessed June 2026.

6

Summary of Product Characteristics for VENCLYXTO (venetoclax). Ludwigshafen, Germany: AbbVie Deutschland GmbH & Co. KG.

7

VENCLEXTA (venetoclax) [Package Insert]. North Chicago, Ill.: AbbVie Inc

The company is expanding both approved and pipeline therapies. New indications could expand the market for existing drugs.

-

DENVER--(BUSINESS WIRE)--SSR Mining Inc. (Nasdaq/TSX: SSRM) (“SSR Mining” or the “Company”) announces that each of the eight nominees listed in the Proxy Statement for the 2026 Annual Meeting of Shareholders (the “Meeting”) were elected as directors of SSR Mining on Thursday, May 7, 2026. Voting results for the election of directors are set out below:

Nominee Name

Votes For

% For

Votes Withheld

% Withheld

Broker Non Vote

Rod Antal

145,639,711

98.69%

1,938,333

1.31%

15,402,274

Thomas R. Bates, Jr.

90,845,964

61.56%

56,732,081

38.44%

15,402,273

Brian R. Booth

146,243,280

99.10%

1,334,764

0.90%

15,402,274

Alan P. Krusi

145,353,727

98.49%

2,224,317

1.51%

15,402,274

Daniel Malchuk

144,910,353

98.19%

2,667,691

1.81%

15,402,274

Laura Mullen

145,801,559

98.80%

1,776,486

1.20%

15,402,273

Kay Priestly

140,344,130

95.10%

7,233,914

4.90%

15,402,274

Karen Swager

123,223,257

83.50%

24,354,788

16.50%

15,402,273

At the Meeting, the shareholders of SSR Mining also approved (i) a non-binding advisory resolution regarding the Company’s approach to executive compensation, and (ii) the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

The voting results for each resolution are set out below:

Votes For

% For

Votes Against

% Against

Votes Withheld

% Withheld

Broker Non Vote

Advisory Vote on

Executive Compensation

79,296,143

53.73%

66,819,982

45.28%

1,461,909

0.99%

15,402,284

Appointment of Auditors

162,777,275

99.88%

0

0.00%

203,043

0.12%

0

About SSR Mining

SSR Mining is listed under the ticker symbol SSRM on the Nasdaq and the TSX.

For more information, please visit: www.ssrmining.com.

More News From SSR Mining Inc.

Back to Newsroom

SSR Mining (SSRM) is rated Buy, reflecting its Americas-focused pivot and strong performance, though no longer a Strong Buy after a significant rally since upgrading them. Q1 results exceeded EPS and revenue estimates, with $210.78M in free cash flow despite production being weighted toward H2 and AISC pressures. The Çöpler sale ($1.5B) is expected to close by the end of Q3 2026, unlocking capital for growth, buybacks, and reducing Turkey-related risk, supporting a potential re-rating as they pivot.

DENVER--(BUSINESS WIRE)--SSR Mining Inc. (Nasdaq/TSX: SSRM) ("SSR Mining" or the “Company") announces that it has entered into a definitive agreement with Lidya Mines to sell its 20% ownership stake and its operatorship position in the Hod Maden development project (the “Project”) for an uncapped 4.0% net smelter return royalty (“NSR”) on 100% of the Project (the “Transaction”).

The royalty consideration received by SSR Mining is expected to deliver an accretive outcome for shareholders. Concurrently with the Transaction, Royal Gold, Inc. (“Royal Gold”), which is a partner in the Project, will sell 15% of its ownership interest in the Project to Lidya Mines in exchange for an uncapped 2.5% NSR on 100% of the Project. Royal Gold’s 2.5% NSR will be issued with substantially the same key terms as the 4.0% NSR issued to SSR Mining. Royal Gold will also hold a fixed price call right to acquire 2.0% of the NSR from SSR Mining for $160 million, expiring 12 months following declaration of commercial production at the Project. Additionally, Royal Gold will hold a consent right on the sale of SSR Mining's NSR prior to January 1, 2028, and a right of first refusal in connection with any sale of the SSR Mining NSR.

Upon entering into the agreements related to the Transaction, Lidya Mines will become operator of the Project. Upon closing of the Transaction, Lidya Mines will own 85% and Royal Gold will own 15% of the Project.

SSR Mining’s total invested capital into Hod Maden, inclusive of upfront acquisition cost, earn-in and capital spend to date is approximately $243 million. With the announcement of this Transaction, SSR Mining will resign as project operator and will have no further funding obligations, with such obligations being assumed by Lidya Mines. The Transaction will be completed on an as-is, where-is basis and SSR Mining will not provide any material post-closing indemnities. The Transaction is expected to close in the third quarter of 2026. The closing of the Transaction will be subject to receipt of regulatory approval from the Turkish General Directorate of Mining and Petroleum Affairs, as well as other consents and approvals that may be required in connection with the Transaction, and other customary conditions.

The Transaction, together with the previously announced sale of the Çöpler mine in Türkiye and acquisition of the Cripple Creek & Victor Mine in Colorado, completes SSR Mining’s strategic refocus to an Americas platform. These transactions reinforce the Company’s position as a leading free cash flow, capital returns-focused gold and silver producer, anchored by its long-lived Marigold and Cripple Creek & Victor operations in the United States.

Following the closing of the Transaction, the 4.0% Hod Maden NSR will strengthen SSR Mining’s existing royalty portfolio, which currently includes NSRs on the San Luis project (4.0%) owned by Highlander Silver, the Pitarrilla project (1.25%) owned by Endeavour Silver, the Rowan property (3.0%) owned by West Red Lake Gold, and the Sunrise Lake property (4.0%) owned by Honey Badger Silver.

About SSR Mining

SSR Mining is listed under the ticker symbol SSRM on the Nasdaq Stock Market and the Toronto Stock Exchange.

For more information, please visit: www.ssrmining.com.

Cautionary Note Regarding Forward-Looking Information and Statements:

This press release includes “forward looking information” within the meaning of applicable securities laws. Forward-looking information can be identified by terminology such as “may”, “will”, “could”, “should”, “expect”, “plan”, “anticipate”, “believe”, “intend”, “estimate”, “projects”, “predict”, “potential”, “continue” or other similar expressions concerning matters that are not historical facts. Statements that refer to projections of our future financial performance, our anticipated growth and trends in our businesses, and other characterizations of future events or circumstances are forward-looking statements, and include, but are not limited to, our ability successfully close the Transaction or our previously announced agreement to sell the Çöpler mine to Cengiz Holding A.Ş. (the “Çöpler Transaction”) within the time periods anticipated, or at all; our ability to obtain any necessary regulatory or other approvals or consents for the Transaction or the Çöpler Transaction that may be required; the successful completion of the Project and the ability of Lidya Mines to generate revenues from the Project; our ability to receive revenues under, and realize the expected returns from, the NSR, and whether and when we elect, and are able, to monetize the NSR; and our ability to strategically refocus our business to the Americas.

Although we believe that the expectations and assumptions on which such forward-looking information and statements are based are reasonable, you should not place undue reliance on the forward-looking information and statements because we can give no assurance that they will prove to be correct. Forward-looking information and statements are subject to various risks and uncertainties which could cause actual results and expectations to differ materially from the anticipated results or expectations expressed in this press release. Important factors that could cause actual results to differ materially from our historical experience, and present projections and expectations are disclosed in our filings that we make on SEDAR+ at www.sedarplus.ca, and on EDGAR at www.sec.gov, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions. Forward-looking information and statements speak only as of the date they are made. Other than as required by law, we do not intend, and undertake no obligation to update any forward-looking information and statements to reflect, among other things, new information or events. The information contained on, or that may be accessed through, our website is not incorporated by reference into, and is not a part of, this document.

More News From SSR Mining Inc.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.

It also includes access to the Zacks Style Scores.

What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.

Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.

The Style Scores are broken down into four categories:

Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.

Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.

Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.

VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.

Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.

That's where the Style Scores come in.

To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.

Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.

Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: SSR Mining (SSRM - Free Report) SSR Mining Inc. is a precious metals miner engaged in the operation, acquisition, exploration and development of gold and silver assets across four key jurisdictions: the United States, Türkiye, Canada and Argentina. Incorporated in British Columbia in 2005, the company is headquartered in Denver, Colorado.

SSRM is a #1 (Strong Buy) on the Zacks Rank, with a VGM Score of A.

It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 6.76; value investors should take notice.

Two analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.61 to $4.38 per share. SSRM also boasts an average earnings surprise of +54%.

With a solid Zacks Rank and top-tier Value and VGM Style Scores, SSRM should be on investors' short list.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.

It also includes access to the Zacks Style Scores.

What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.

Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.

The Style Scores are broken down into four categories:

Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.

Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.

Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.

VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.

How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.

It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.

That's where the Style Scores come in.

To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.

As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.

Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: SSR Mining (SSRM - Free Report) SSR Mining Inc. is a precious metals miner engaged in the operation, acquisition, exploration and development of gold and silver assets across four key jurisdictions: the United States, Türkiye, Canada and Argentina. Incorporated in British Columbia in 2005, the company is headquartered in Denver, Colorado.

SSRM is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.

Momentum investors should take note of this Basic Materials stock. SSRM has a Momentum Style Score of A, and shares are up 1.3% over the past four weeks.

Two analysts revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.61 to $4.38 per share. SSRM boasts an average earnings surprise of +54%.

With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, SSRM should be on investors' short list.

Vancouver, British Columbia--(Newsfile Corp. - June 1, 2026) - Phenom Resources Corp. (TSXV: PHNM) (FSE: 1PY0) ("Phenom" or the "Company") is pleased to announce a letter of intent governing an expected non-brokered private placement investment in Phenom by SSR Mining Inc. ("SSR") and proposed joint venture with SSR for the Company's Dobbin Property located in Nevada.

SSR Mining Inc. is a US$6.5B Denver-based gold and silver mining company and the third largest gold producer in the United States. SSR Mining has a portfolio of operating, development and exploration assets across the Americas, including locations in the USA, Canada, and Argentina.

SSR's core operating assets include:

Marigold mine: An open-pit gold mine in Nevada, USA. Cripple Creek & Victor (CC&V) mine: An open-pit gold mine in Colorado, USA. Seabee mine: An underground gold mine in Saskatchewan, Canada. Puna operations: Located in the Jujuy province, Puna is the largest silver mine in ArgentinaPrivate Placement - Strategic Investment

It is proposed that SSR will become a strategic investor in the Company through the non-brokered private placement purchase of 9.9% of the Company's issued and outstanding common shares (calculated on a non-diluted basis, after giving effect to this share issuance) (the "Strategic Investment"). Consequently, under the Strategic Investment, the Company proposes to issue 13,518,353 common shares (the "Shares") to SSR at a price of CAD$0.40/share for total proceeds of CAD$5,407,341.20 (approx. US$3,917,370). The proceeds received from the Strategic Investment are proposed to be used as follows: (i) US$1.3 million will be used towards the remaining payment and work commitments owed by the Company to fully earn a 100% interest in the Dobbin Project; (ii) US$2.5 million will be available for unallocated general working capital of the Company; and (iii) the balance (approx. US$117,370) will be used for general working capital purposes relating to the Dobbin Project.

The Shares will be subject to a statutory hold period expiring four months and one day after their issuance, in accordance with applicable securities laws and the policies of the TSX Venture Exchange (the "TSXV"). In addition, SSR has agreed to voluntarily restrict the disposition of the Shares for a period of one (1) year from the closing date (the "Restricted Period"); provided that SSR may sell up to an aggregate of 500,000 Shares in any calendar month during the Restricted Period, upon prior written notice to Phenom. This limit is fixed for each month, and any undisposed Shares for a particular month will not be added to the next or any succeeding month's limit.

In conjunction with the Strategic Investment, it is proposed that the Company will grant to SSR, for so long as SSR holds a 4.9% or greater ownership interest in Phenom, the right, at the sole discretion of SSR, to maintain that level of ownership interest or to increase its ownership percentage up to a maximum of 19.9% of the outstanding Phenom shares, through participation and top-up rights.

The Strategic Investment is subject to the approval of the TSXV.

Sale of 15% Interest in Dobbin Project and Resulting JV

As part of the non-binding letter of intent ("LOI"), Phenom and SSR have also agreed upon a framework for the sale by Phenom of a 15% interest in the Dobbin Project to SSR for a further US$4,000,000.00, and the consequent joint venture arrangement to be carried on by the two companies in respect of the Dobbin Project. It is proposed that all funds paid by SSR to purchase its 15% interest will be used to advance the Dobbin Project. The LOI provides a binding two-year standstill provision and imposes standard confidentiality obligations on the parties.

The LOI also provides for a binding 30-day exclusivity period, during which time the parties have agreed to negotiate exclusively towards the execution of a definitive agreement relating to the Dobbin Project transaction. There can be no assurance that the parties will enter into a definitive agreement or that the proposed transactions will be completed. The Company will provide updates on the transactions if and when they become available.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States of America. The securities have not been and will not be registered under the United States Securities Act of 1933 (the "1933 Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons (as defined in the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration is available.

About Phenom Resources Corp.
Phenom has 100% interest in the Carlin Gold-Vanadium Project, located six miles south from the town of Carlin, Nevada, and Highway I-80 in Elko County, which hosts the Carlin Vanadium deposit, North America's largest highest grade primary vanadium resource. The Company has 100% interest in Crescent Valley gold Project, a Bonanza high grade gold vein-type target and an IOCG target and options on two gold projects in Nevada - the Dobbin and King Solomon Properties, which are Carlin Gold-type targets.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking information
Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events or the Company's future performance and include, but is not limited to, statements regarding the intended use of proceeds of the Offering, including funding work programs on the Company's exploration properties and for general working capital purposes, the receipt of final approval of the TSX Venture Exchange, and other statements that are not historical facts. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether or not such results will be achieved. Actual results could differ materially from those anticipated due to a number of factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. Readers should not place undue reliance on forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required under applicable securities regulations.

Not for distribution to United States newswire services or for dissemination in the United States.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/299597

Source: Phenom Resources Corp.

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Gold and silver are eternally attractive metals, but lately they haven't been ideal investments. On recent declines in the prices of the two, SSR Mining (SSRM +3.46%) -- which mines both metals -- saw its stock price decrease by more than 3% on Tuesday.

The yield problem The rout in precious metals started last Friday, just after the federal government's Bureau of Labor Statistics released its latest monthly employment report. The striking feature of this digest was the 172,000 new jobs created in May, far higher than the consensus estimate of 80,000. Immediately, and understandably, this led to widespread speculation that the Federal Reserve is more likely to raise than cut interest rates in the near future.

Image source: Getty Images.

This triggered a sell-off in bonds, since higher rates mean higher interest paid on future issues. When a bond's price falls, its yield rises. That makes these yield-bearing investments especially attractive when compared to nonyielding investments -- gold and silver don't pay coupons, after all. Subject to that dynamic, precious metals have generally been on the downswing since Friday.

Broadly speaking, companies that mine precious and base metals are pure plays. What's more, mining is a capital-intensive activity with many fixed costs. Therefore, movements in gold/silver/etc. prices can and will disproportionately affect the performance of the SSR Minings of this world.

Today's Change

(

3.46

%) $

0.91

Current Price

$

27.23

Diminished shine Many might consider these latest price movements corrections, as both gold and silver had sustained bull runs that culminated in all-time highs at the beginning of this year. SSR Mining was indisputably a beneficiary of this, to the point where it has sufficient financial "padding" to withstand a downturn. Still, I think the possibility of rate hikes will rise, if anything, so now might be a good time for current stockholders to sell out of their positions.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

GME stock is moving. See the chart and price action here.  Cohen joined Anthony Pompliano on the "From the Desk of Anthony Pompliano" podcast and explained why he wants to acquire eBay. 

“I Want to Own eBay“GameStop has proposed acquiring eBay for $125 per share in a half-cash, half-stock deal, with Cohen saying GameStop has about $9 billion in cash and a $20 billion financing commitment from bankers. 

He framed the bid as a shareholder-friendly combination that would let eBay investors take part cash while rolling the rest into a combined company led by him.

"It’s within my circle of competence," Cohen said. "It’s a business that I understand. It’s the second-largest e-commerce asset in the United States."

Cohen argued eBay is "under earning" and said he could "make a really big impact in terms of the profitability in the short term, but more important in the long term."

"It’s something where I want to run eBay. I want to own eBay. I want eBay to be a much,  much larger business," Cohen said.

He said his Chewy experience is central to the thesis.

"E-commerce is in my wheelhouse and there’s no asset in my view that has as much potential as eBay," Cohen said.

Cohen is UndeterredeBay rejected GameStop's proposal, calling the offer "not credible or attractive." 

Cohen argued the response was expected, saying the deal is "not attractive to the board and the management team" because they would be replaced, but "it's very attractive to shareholders."

He contrasted his approach with eBay's current leadership, saying, "I don’t get paid unless I build a much larger business and I want to turn eBay into something much larger."

He also took aim at eBay's expense structure. 

"I mean, it’s a business that’s spending over $5.5 billion on $11 billion in revenue to run a business that essentially has no inventory and is very asset light," Cohen said, adding that he is "committed to $2 billion in cost cuts at eBay." 

He Likes the BusinessCohen told Pompliano that he is prepared to keep pressing the matter directly with shareholders.

"We’re going to do whatever we obviously need to do in order to bring this proposal in front of the true owners of the business," he said.

Cohen summed up his eBay motivations simply: "I want the business. I want the business."

GME Price ActionThe chart below shows the one-year price action for GME:

GME Price Action: GameStop stock was down 0.22% at $22.34 at the time of publication on Wednesday, according to Benzinga Pro.

Over the past month, GME has declined about 4.53% versus a 9.5% rise in the S&P 500 and is up roughly 10% year-to-date compared to the index’s 8.2% gain.

Photo: Jillian Cain Photography / Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

There’s not a single trader or sophisticated investor I have spoken to who believes Ryan Cohen, the CEO of troubled video-game retailer GameStop, is really going to buy eBay. And yet, I can’t count this guy out – and neither should you. 

Yes, there are plenty of reasons to doubt. EBay is five times GameStop’s size. The meme investor cult that has followed 40-year-old Cohen doesn’t extend much beyond the fevered swamps of retail stock picking. 

Cohen’s recent disclosures about his bid also haven’t helped his cause. His uneven and sometimes evasive interview on CNBC has been universally panned, including his laconic response to questions about how he plans to finance the deal. 

There are plenty of reasons to doubt GameStop CEO Ryan Cohen’s pursuit of eBay. But don’t count him out yet. Jack Forbes / NY Post Design “The full details are on our website,” Cohen assured his interlocutors, even though simple math – $9 billion in cash plus $20 billion in borrowed money – doesn’t get you to eBay’s market cap of $53 billion.

It was the joke of last week’s Milken Global Conference, the yearly confab of Wall Street power players.

Meanwhile, the typical eBay shareholder has done well over the past five years. It’s a profitable e-commerce business under current management.

So it’s no surprise that eBay gave Cohen the old Heisman this week, rejecting his offer as “neither credible nor attractive.” Most people on Wall Street – and probably the eBay board – are concluding that he will make up the financing difference by further diluting his GameStop shareholders.

What eBay investor wants shares of a barely profitable retailer that sells videos in malls people don’t go to anymore and which, by the way, has a huge position in Bitcoin?

The typical eBay shareholder has done well over the past five years. It’s a profitable e-commerce business under current management. REUTERS Of course, all of this is more than fair. But here’s why I’m also skeptical of the Cohen skeptics. 

GameStop is a lousy business, which Cohen readily admits, but somehow he has made it work. Cohen, the founder of the successful pet supplies site Chewy, took over GME in 2023 just after the height of the meme mania had sent its shares soaring. 

They’re now well off their highs, but Cohen has done a good job operationally, shedding stores and accumulating cash by diluting shareholders. That’s exactly what he’s supposed to do. Yes, its stock is still buoyed by meme mania, but its balance sheet is strong.

GameStop has a $10 billion market cap. Getty Images Other meme stocks have imploded; GME has a $10 billion market cap.

He’s also smartly looking for an exit ramp for GME, a floundering business. It’s why he made a foray into crypto and why he’s making his move against eBay.

Charlie Gasparino has his finger on the pulse of where business, politics and finance meet Sign up to receive On The Money by Charlie Gasparino in your inbox every Thursday.

Thanks for signing up!

Bob Sloan, the founder of S3 Partners and my partner in the Risk and Return podcast, has been around Wall Street for years. He sniffs a method to the alleged madness in Cohen’s eBay bid. 

“He’s in the game for something, it might not be this, but he’s in the game,” he tells me.

Cohen seems undeterred by eBay’s stiff arm and suggested he might make a hostile bid for the company on Wednesday.

Yes, it all sounds crazy – but would it be any crazier than his purchase of GameStop?

By You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.

Ebay launched 'The NYC Edit' in March, an online editorial guide highlighting what tastemakers are buying and selling. Noam Galai/Getty Images for eBay EBay has been making headlines recently.

Despite being seen as the pioneer of online resale, the 30-year-old e-commerce platform has struggled to shake its reputation as the internet's flea market. But when GameStop CEO Ryan Cohen made an unsolicited bid to buy the company, eBay doubled down on the idea that it's better off alone, and investors scoffed.

The company is having a glow-up, and fashion is playing a big part in its growth. In February, it reached an agreement to buy Depop, the resale platform loved by Gen Z, for $1.2 billion. The deal has not yet been finalized.

"One of the things that you can't argue with, we've been around for 30 years," Kirsty Keoghan, general manager of EU Fashion & Luxury at eBay, told Business Insider. "We are the OG of buying and selling preloved fashion."

When newer, buzzier competitors emerged and helped reshape consumer perceptions of secondhand shopping, eBay had lost its luster. However, through savvy partnerships, working with celebrities, and improving its user experience, the resale OG is regaining its cool again.

Kirsty Keoghan has worked at eBay for over 15 years.  eBay It started with trustEbay's shares are up around 185% since Jamie Iannone took over as CEO in April 2020 and launched a turnaround effort, and up over 30% year-to-date.

In its first quarter results, released in April, revenue was up 19% year-on-year. Fashion saw double-digit year-on-year growth, led by its luxury, streetwear, and pre-loved clothing focus categories.

A key step in CEO Jamie Iannone's turnaround strategy was to home in on its verticals by making focus categories within them. This was to attract enthusiast buyers, including sneakerheads and vintage luxury lovers. It kicked off this transformation by implementing authenticity guarantees within these focus categories.

CEO Jamie Iannone's strategy was to lean into eBay's verticals.  Bloomberg/Getty Images It started with sneakers in the US in 2020 and has since expanded to other markets and products. Most recently, it integrated a luxury watch authentication service that flags stolen watches in the UK.

"It's [trust] important for everybody when shopping online, particularly with pre-loved," Keoghan said. "But I just think particularly for luxury, it's such an important part of our strategy."

From 'Love Island' to the Met GalaAnother key part of eBay's fashion strategy has been getting involved in cultural moments in order to amp up its visibility and cool factor.

The company teamed up with Vogue and singer-songwriter SZA to source her outfit for the 2026 Met Gala. It has been partnered with popular TV series "Love Island" in the UK since 2022, and has worked with some of the biggest American influencers, such as Emma Chamberlain.

Ebay has built relationships with celebrity stylists in an attempt to have items sourced from its platform appear organically in cultural moments.

One of its ambassadors, celebrity stylist Harry Lambert, dressed Harry Styles in a pre-loved outfit sourced from eBay for a shoot for his latest album launch.

SZA's outfit at the 2026 Met Gala was sourced from eBay.  Mike Coppola/Getty Images "The reason why we've done that is so that we can put pre-loved fashion at the forefront of some of these really big fashion moments and get people to think about fashion really differently," Keoghan said.

Fierce competitionDespite the trendy collaborations and the popularity of pre-loved fashion among Gen Z consumers, Keoghan said eBay does not have a specific core customer in mind.

"We've got all of the other categories, which I think for us is like our superpower because you can come and buy fashion and you can also go and buy or sell a desk or a sofa," Keoghan said.

Since eBay's launch, younger companies such as European-headquartered Vinted and US-based Poshmark have emerged, making the secondhand e-commerce market fiercely competitive. When Vinted dropped its seller fee, eBay followed suit in the UK and Germany. It is yet to do the same in the US.

Ebay's 'The NYC Edit' campaign in March included a physical retail pop-up.  Noam Galai/Getty Images for eBay Keoghan said she welcomes the competition. "I think it makes us all up our game," she said.

No longer wanting to play catch-up, eBay is pressing ahead with AI features, such as AI-generated descriptions and a background enhancement tool, to reduce seller friction as much as possible.

"Using innovation and technology to do that is really key for us at eBay," she added. "We're just trying to continue to make those better and better and better. So it makes it really easy for our customers."

Read next

Roya Shahidi You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.

Roya is a business news fellow at Business Insider's London office.Before joining Business Insider, she worked as a reporter at financial newswire Alliance News and was a platforms and publishing intern at The Wall Street Journal. Roya graduated from City St George's, University of London with an MA in International Journalism. You can contact her via email at [email protected] or message her securely on Signal at royashahidi.36

Fashion

Item 1 of 2 A man walks in front of a GameStop store in the Jackson Heights neighborhood of New York City, New York, U.S. January 27, 2021. Picture taken January 27, 2021. REUTERS/Nick Zieminski/ File Photo

[1/2]A man walks in front of a GameStop store in the Jackson Heights neighborhood of New York City, New York, U.S. January 27, 2021. Picture taken January 27, 2021. REUTERS/Nick Zieminski/ File Photo Purchase Licensing Rights, opens new tab

CompaniesMay 20 (Reuters) - GameStop (GME.N), opens new tab increased its stake in eBay (EBAY.O), opens new tab to about 6.6% from ​around 5%, according to a regulatory filing, the latest ‌step in the videogame retailer's push to buy the e-commerce giant.

"Together, the 25,000 shares of Common Stock beneficially owned directly and the shares of ​Common Stock underlying Put/Call Pairs constitute approximately 6.55% of ​the outstanding shares of Common Stock," the filing made by ⁠GameStop with the U.S. Securities and Exchange Commission said.

Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.

Earlier this ​month GameStop Chief Executive Officer Ryan Cohen surprised Wall Street with ​an unsolicited offer to buy eBay for roughly $56 billion.

EBay, which is roughly five times as large as GameStop, rejected the offer, calling the proposal "neither credible nor ​attractive."

Disappointed but not deterred, Cohen has said in interviews that ​he was sticking with his plan to try and buy the company and ‌would ⁠take the offer directly to shareholders if needed.

By increasing his holdings, he might be laying the groundwork to pursue options like calling a special meeting, analysts said.

A representative for Cohen had no comment ​beyond the regulatory ​filing.

EBay's shares ⁠jumped 35% this year as it reported strong first-quarter earnings amid a fresh focus on high-growth ​categories like collectibles. Since Jamie Iannone took over as ​eBay ⁠CEO in 2020 after other activist investors forced his predecessor out, eBay's stock has climbed more than 201%.

GameStop shares are up about ⁠9% this ​year but have fallen 65% since ​Cohen took over as chairman in 2021.

Reporting by Harshita Mary Varghese in Bengaluru and ​Svea Herbst-Bayliss in New York; Editing by Sriraj Kalluvila, Kirsten Donovan

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Key Takeaways MercadoLibre faces margin pressure as shipping, fulfillment and fintech investments continue rising.eBay is benefiting from stronger advertising momentum and resilient category-focused marketplace demand.eBay trades at a higher valuation multiple than MercadoLibre, supported by stronger profitability. MercadoLibre (MELI - Free Report) and eBay (EBAY - Free Report) are among the most recognized names in e-commerce, connecting millions of buyers and sellers through large online marketplace ecosystems. MercadoLibre has built a dominant presence in Latin America through its integrated commerce and logistics network, while eBay continues to strengthen its global marketplace with a focus on categories such as collectibles, luxury goods and automotive parts.

Both companies are expanding seller tools, advertising offerings, shipping capabilities and AI-driven shopping experiences to drive marketplace engagement and transaction growth. However, their approaches toward growth, profitability and marketplace monetization have increasingly diverged. Let’s delve deeper to determine which e-commerce platform holds the edge.

The Case for MELIMercadoLibre’s platform is expected to remain under pressure as growth depends on sustained spending across shipping, fulfillment and merchant incentives. Seller fees have been lowered in selected categories and free shipping programs continue to expand, driving stronger commerce volumes but limiting operating leverage and compressing platform margins. Revenues rose 49% year over year in the first quarter of 2026, while operating margin compressed 600 basis points to 6.9% as investment intensity accelerated.

MELI continues to push deeper into advertising, AI-driven search and seller discovery tools to improve conversion and buyer engagement. However, these capabilities are still being developed alongside elevated infrastructure expansion, which is expected to keep technology and operating costs high over the near term. MercadoLibre’s marketplace model increasingly appears dependent on continuous ecosystem reinvestment rather than margin expansion.

A further concern weighing on MELI is the growing drag from fintech operations, which contributes to the widening performance gap between MELI and eBay. Credit card issuance, consumer loans and longer duration lending continue to expand aggressively, keeping provisioning elevated and profitability under pressure. Mercado Pago’s monthly active users grew 29% year over year in the first quarter of 2026, while the credit portfolio nearly doubled to $14.6 billion, a trend expected to weigh on earnings visibility going forward.

The Zacks Consensus Estimate for MELI's second-quarter 2026 earnings is pegged at $8.69 per share, down 25.5% over the past 30 days, indicating a year-over-year decline of 15.71%.

The Case for EBAYeBay’s e-commerce platform is expected to benefit from a more balanced marketplace strategy centered on seller engagement, advertising monetization and category-focused commerce expansion. The company continues strengthening its presence across collectibles, luxury goods, automotive parts and recommerce categories, where transaction quality and enthusiast demand remain relatively resilient. Gross merchandise volume increased 14% year over year in the first quarter of 2026, supported by stronger momentum across fashion, motors and collectibles. eBay Live is operational across seven markets globally, and cross-border trade has been supported through expanded shipping solutions, including eBay International Shipping in Canada and SpeedPAK across Germany and six additional markets.

eBay continues to expand AI-driven seller tools, conversational search capabilities and advertising solutions to improve conversion rates and marketplace engagement. AI-powered listing enhancements are expected to simplify seller onboarding and improve listing productivity, while advertising offerings continue supporting take rate expansion across the platform. First-party advertising revenue grew 28% to $555 million in the first quarter of 2026, benefiting from stronger promoted listings adoption and higher seller participation across the marketplace.

eBay's marketplace model is expected to remain relatively disciplined from a profitability standpoint compared with MELI. The company continues investing in shipping solutions, live commerce and marketplace innovation without materially disrupting earnings leverage. Operating income increased 18% year over year in the first quarter of 2026, reflecting healthy operational execution alongside marketplace growth.

The Zacks Consensus Estimate for eBay’s second-quarter 2026 earnings is pegged at $1.5 per share, up by a penny over the past 30 days. The figure indicates an 9.49% increase year over year.

Price Performance and Valuation of MELI and EBAYIn the year-to-date period, EBAY shares have rallied 32.9% while MELI shares have declined 17.4%. EBAY's rally has been supported by its global marketplace exposure and stable execution, whereas MELI's share price weakness reflects the strain of rising costs and margin uncertainty.

EBAY vs. MELI: YTD Performance
Image Source: Zacks Investment Research

On a forward 12-month Price-to-Sales basis, eBay trades at 4.1x compared to MELI's 1.89x. While MELI's lower multiple may appear attractive, it reflects ongoing margin compression and earnings uncertainty. eBay's premium is supported by stronger profitability, disciplined capital allocation and consistent earnings growth, making the valuation gap appear fundamentally justified.

EBAY vs. MELI: Valuation
Image Source: Zacks Investment Research

ConclusioneBay's global marketplace exposure, stable margins and growing advertising revenues give it a clear edge over MercadoLibre. MELI's margin compression, elevated spending and expanding fintech risk continue to weigh on its investment case.

eBay carries a Zacks Rank #3 (Hold), while MELI has a Zacks Rank #5 (Strong Sell) at present.

You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

On May 27, 2026, eBay Inc EBAY shares fell 4.3%, closing at $110.36. Over the past week, the stock has declined by 7.2%, despite a solid YTD gain of 27.1% and a remarkable 54.5% increase over the past year. The stock has traded within a 52-week range of $71.69 to $119.31.

GF Value™ verdict: Shares are currently priced at $110.36, which is 37.8% above the GF Value of $80.09, indicating the stock is overvalued.GF Score™: eBay has a score of 82/100, categorized as strong, suggesting it has solid fundamental characteristics.Most notable signal: Insider activity shows that insiders sold $20.1 million worth of shares over the last three months, with no notable buying activity. Is EBAY Overvalued or Undervalued? eBay's current price of $110.36 is significantly higher than the estimated GF Value™ of $80.09, leading to an overvaluation of 37.8%. This gap between the current market price and the intrinsic value highlights a lack of margin of safety for potential investors, suggesting that the current pricing may not be sustainable in the long run. The GF Valuation label indicates that the stock is significantly overvalued, raising concerns about the potential for price correction if the market adjusts to align more closely with its fundamental value.

While eBay has demonstrated strong performance metrics over the past year, the overvaluation risk cannot be overlooked. Investors may face losses if the shares revert toward their intrinsic value. GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates. This emphasizes the importance of understanding intrinsic value in the context of current market conditions.

How Does EBAY's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 25.0x 16.0x Forward P/E 18.0x eBay's current P/E (TTM) of 25.0x stands at 57% above its 5-year median P/E of 16.0x, indicating that the stock is trading at a higher valuation than it has historically. The forward P/E of 18.0x suggests some expectation of growth, yet it still aligns with the overvalued status indicated by the GF Value™ verdict. This P/E analysis concurs with the overall assessment of eBay being overvalued, as it reflects a significant premium over historical norms.

What Does EBAY's GF Score™ Tell Us? The GF Score™ ranks stocks from 0 to 100 based on five key aspects: Financial Strength, Profitability, Growth, Valuation, and Momentum. Stocks with higher GF Score™ values have been found to generate higher long-term returns (backtested 2006-2021).

Metric Rating GF Score™ 82 Financial Strength 6/10 Profitability 8/10 Growth 6/10 Valuation 5/10 Momentum 10/10 eBay's GF Score™ of 82 indicates strong overall performance, particularly in profitability (8/10) and momentum (10/10), suggesting the company has maintained solid earnings and positive stock price movement. However, the Valuation score of 5/10 reflects potential concerns regarding its current market price relative to intrinsic value. Financial strength is moderate at 6/10, implying a stable balance sheet, but the growth score of 6/10 may indicate that future expansion could be a challenge. Overall, while there are strong attributes, the valuation aspect signals caution.

What Are Insiders Doing with EBAY Stock? Recent insider activity has shown a significant trend towards selling, with insiders offloading $20.1 million in shares over the last three months without any notable buying. This pattern may suggest a lack of confidence in the stock's current pricing or future performance from those who are most familiar with the company's operations. Such selling activity can often be viewed as a bearish signal in the market, leading to further scrutiny of the stock's current valuation.

What This Means for Investors Based on the GF Value™ assessment, eBay Inc EBAY is currently overvalued. The significant gap between the current market price and the intrinsic value suggests that investors may want to exercise caution, as the stock could be subject to downward pressure if the market correction occurs.

For the complete analysis, visit the eBay Inc EBAY stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.

Frequently Asked Questions What is EBAY's GF Score™?

eBay's GF Score™ is 82/100, indicating a strong overall performance based on key fundamental aspects.

Is EBAY overvalued or undervalued?

eBay is currently overvalued, with its market price significantly above the estimated GF Value™.

What is EBAY's P/E ratio?

eBay's P/E (TTM) is 25.0x, which is substantially higher than its 5-year median P/E of 16.0x, indicating a premium valuation.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

A month has gone by since the last earnings report for eBay (EBAY - Free Report) . Shares have added about 8.4% in that time frame, outperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is eBay due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the latest earnings report in order to get a better handle on the important catalysts.

eBay Q1 Earnings & Revenues Surpass Estimates, Both Increase Y/YeBay Inc. reported first-quarter 2026 non-GAAP earnings of $1.66 per share, which beat the Zacks Consensus Estimate by 5.06%. The bottom line increased 21.2% year over year.

Net revenues of $3.09 billion beat the Zacks Consensus Estimate by 1.98%. The figure increased 19% year over year on a reported basis and 17% on an FX-neutral basis.

eBay's first-party advertising products generated revenues of $555 million in the reported quarter, up 33% on an as-reported basis and 28% on an FX-neutral basis.

Total advertising offerings yielded $581 million in revenues, representing 2.6% of gross merchandise volume (GMV).

EBAY's active buyer base was 136 million at the end of the first quarter, increasing 1% year over year. Excluding the Tise acquisition, active buyers stood at 135 million.

GMV Details for EBAYGross Merchandise Volume reached $22.2 billion, reflecting an 18% year-over-year increase on a reported basis and 14% on an FX-neutral basis. This indicates strong buyer and seller engagement across the platform, reinforcing eBay’s marketplace strength.

The total GMV is categorized into two parts. U.S. GMV totaled $11.5 billion, accounting for 51.8% of total GMV. The figure rose 26.9% year over year. International GMV was $10.7 billion, accounting for 48.2% of total GMV. The figure increased 10.4% year over year.

EBAY's Q1 Operating DetailsOperating expenses of $1.68 billion grew 31.2% year over year. As a percentage of net revenues, the figure expanded to 54.3% from 49.4% in the year-ago quarter.

The non-GAAP operating margin was 29.4% in the first quarter, contracting 20 basis points (bps) year over year. The decline was modest, indicating stable profitability despite higher investments.

EBAY's Balance Sheet & Cash FlowAs of March 31, 2026, cash and cash equivalents and short-term investments were $3.86 billion, up from $2.92 billion as of Dec. 31, 2025.

Long-term debt decreased sequentially to $5.99 billion at the end of the first quarter of 2026 compared with $6.0 billion in the prior quarter.

Cash flow from operating activities was $970 million in the first quarter, up from $595 million in the previous quarter, reflecting a sequential improvement in cash generation.

Free cash flow increased sequentially to $898 million in the first quarter compared with $478 million in the previous quarter.

The company repurchased $500 million worth of shares and paid out cash dividends of $139 million in the reported quarter. eBay had approximately $2.3 billion remaining under its buyback authorization as of March 31, 2026.

eBay’s Strategic Initiatives and OutlookDuring the quarter, eBay announced an agreement to acquire Depop, expanding its presence in the consumer-to-consumer fashion marketplace. The move is expected to strengthen engagement with younger users.

For the second quarter of 2026, eBay expects revenues in the range of $2.97 billion to $3.03 billion. On an FX-neutral basis, revenue growth is anticipated to be 8%-10%.

GMV for the second quarter is likely to be in the range of $21.3 billion to $21.7 billion. On an FX-neutral basis, GMV growth is anticipated to be 8%-10%.

Non-GAAP earnings per share are anticipated to be between $1.46 and $1.51. GAAP diluted EPS from continuing operations is expected in the range of $1.09 to $1.14.

How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a flat trend in estimates review.

VGM ScoresCurrently, eBay has a average Growth Score of C, a score with the same score on the momentum front. Charting a somewhat similar path, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for value investors.

Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.

Outlook eBay has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.